Johnson & Johnson

Johnson & Johnson announces Phase 2b SunRISe-1 study results showing 84% complete response rate with TAR-200 for BCG-unresponsive high-risk non-muscle-invasive bladder cancer, presented at ESMO 2024.

Amivantamab combined with chemotherapy showed promising antitumour activity in RAS/BRAF WT mCRC patients not previously treated with EGFR therapy, with a median duration of response of 7.4 months and 21% proceeding to curative intent surgery.

Legend Biotech Corporation (NASDAQ:LEGN) ranks 10th among hedge funds' top biotech stock picks, with 24 hedge fund investors and RA Capital's $332 million stake. LEGN, a commercial-stage biotech developing cancer treatments, focuses on its Carvytki drug for myeloma, which saw $186 million in Q2 sales, a 19% sequential growth.

Updated Phase 3 MARIPOSA-2 study results show RYBREVANT® (amivantamab) plus chemotherapy significantly improves post-progression outcomes and overall survival in previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 19 deletions or L858R mutations, compared to chemotherapy alone.

Updated MARIPOSA-2 study results show RYBREVANT® plus chemotherapy significantly improves post-progression outcomes in previously treated NSCLC patients with EGFR exon 19 deletions or L858R mutations, with a favorable trend toward improved overall survival compared to chemotherapy alone. Data presented at ESMO 2024 Congress.

J&J's Rybrevant shows promise in colorectal cancer, with Phase II data suggesting it makes metastatic patients eligible for curative surgery, leading to a 49% ORR in the OrigAMI-1 study.

RYBREVANT® (amivantamab-vmjw) + chemotherapy showed promising antitumor activity in RAS/BRAF WT mCRC patients not previously treated with anti-EGFR therapy, with a median duration of response of 7.4 months. 21% of patients proceeded to curative-intent surgery.

RYBREVANT® plus standard of care showed significant and sustained improvement over chemotherapy alone in post-progression outcomes for previously treated NSCLC patients with EGFR exon 19 deletions or L858R mutations, with a favorable trend toward improved overall survival.

Merck's stock has risen 72% in 5 years, driven by Keytruda's success, but faces uncertainty as Keytruda's patent expires in 2028. Merck forecasts 2024 revenue growth of 5-7% and seeks new blockbusters, while competition from biosimilars and alternative treatments poses risks.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.